Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
04 05 2020
04 05 2020
Historique:
received:
22
10
2019
accepted:
20
12
2019
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
3
8
2021
Statut:
epublish
Résumé
We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing interval were associated with clinical and demographic patient characteristics or natalizumab receptor occupancy (RO) on leukocytes. In this cross-sectional study of 40 patients with relapsing-remitting MS (RRMS) receiving natalizumab at the Department of Neurology, Haukeland University Hospital, we recorded clinical and demographic data including age, body mass index (BMI), working status, smoking habits, disease characteristics, treatment duration, vitamin D levels, and wearing-off symptoms. We quantified neurofilament light chain in serum and measured natalizumab RO in leukocyte subtypes by high-parameter mass cytometry. Associations with wearing-off symptoms were analyzed. Eight (20.0%) patients who reported regular occurrence of wearing-off symptoms, 9 (22.5%) who sometimes had wearing-off symptoms, and 23 (57.5%) who did not have wearing-off symptoms were evaluated. Patients who regularly had wearing-off symptoms had lower natalizumab RO than patients who reported having such symptoms sometimes or never. The former group also had higher BMI and higher frequency of sick leave. High BMI was associated with low RO. No other demographic or disease characteristics were associated with the phenomenon. Low RO may explain the wearing-off phenomenon observed in some patients with RRMS treated with natalizumab, and high BMI may be the underlying cause.
Identifiants
pubmed: 32019768
pii: 7/3/e678
doi: 10.1212/NXI.0000000000000678
pmc: PMC7051203
pii:
doi:
Substances chimiques
Immunologic Factors
0
Natalizumab
0
Integrin alpha4
143198-26-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Front Neurol. 2019 Apr 05;10:338
pubmed: 31024432
Anal Chem. 2009 Aug 15;81(16):6813-22
pubmed: 19601617
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Int J MS Care. 2014 Summer;16(2):92-8
pubmed: 25061433
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
N Engl J Med. 2006 Mar 2;354(9):899-910
pubmed: 16510744
Neurology. 2019 Oct 8;93(15):e1452-e1462
pubmed: 31515290
Cytometry B Clin Cytom. 2018 Mar;94(2):327-333
pubmed: 28378895
N Engl J Med. 2012 May 17;366(20):1870-80
pubmed: 22591293
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
J Neurol. 2015 Mar;262(3):781-2
pubmed: 25663410
BMC Bioinformatics. 2010 Nov 04;11:546
pubmed: 21050468
Ther Adv Neurol Disord. 2014 Sep;7(5):227-31
pubmed: 25342976
J Clin Pharmacol. 2017 Aug;57(8):1017-1030
pubmed: 28398628
Mult Scler. 2010 Nov;16(11):1385-92
pubmed: 20739335
Cytometry A. 2019 Mar;95(3):314-322
pubmed: 30688025
PLoS One. 2012;7(4):e35843
pubmed: 22558238
Neurology. 2019 Oct 22;93(17):e1579-e1586
pubmed: 31551258
Cytometry A. 2016 Jun;89(6):601-7
pubmed: 27061608
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2770-7
pubmed: 24979804
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Mult Scler Relat Disord. 2019 Jun;31:65-71
pubmed: 30939392
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9
pubmed: 26917698